Compare

Haleon/$HLN

1D1W1M3M6MYTD1Y5YMAX

About Haleon

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Health
Primary listing
NYSE
Employees
24,535
Headquarters
Weybridge, United Kingdom
Website
www.haleon.com

Haleon Metrics

BasicAdvanced
$40B
37.90
$0.24
0.25
$0.19
1.35%

What the Analysts think about Haleon

Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Analyst projections of the future price of Haleon stock.

Bulls say / Bears say

Oral Health remains a clear growth engine: Q3 organic revenue rose 8.8%, supported by innovation and strong Sensodyne sales. That gives Haleon a resilient brand-led area to build on while other categories are softer. (Haleon)
Haleon is improving its US retail execution, with better shelf positions at Walmart and Target. Reuters reported that NielsenIQ data showed its US consumer-health market share had risen each month since February, suggesting the turnaround is gaining traction. (Reuters)
Profit and cash generation are holding up better than sales: first-half adjusted operating profit rose 8.2%, free cash flow was £769m and the company still expects high-single-digit adjusted operating-profit growth for 2026. It has also announced a further £500m share buyback. (Haleon, Haleon)
Haleon cut its 2026 organic revenue-growth outlook to around 2.5%, from 3%–5% previously, after Q3 growth fell short of expectations. Weak cold-and-flu demand and a one-off Brazil distribution transition add near-term pressure. (Haleon)
A Chinese raw-material classification change has stopped imports of Centrum’s affected over-the-counter products, and Haleon says there is no near-term solution. The company generated about £75m of revenue from these products in 2025, so a prolonged disruption could weigh on growth. (Haleon)
Growth remains uneven beyond Oral Health: Q3 revenue fell 0.6% in Europe, while Respiratory Health declined 2.0% and vitamins, minerals and supplements fell 0.5%. Group growth was mostly price-led, with just 0.5% from volume and mix, raising questions about underlying demand. (Haleon)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Haleon Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Haleon Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Haleon News

AllArticlesVideos

UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon

Proactive Investors3 weeks ago

Unilever on JP Morgan positive watch as Haleon faces caution

Proactive Investors1 month ago

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Proactive Investors2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.